Search SNOA
Sonoma Pharmaceuticals, Inc.
Nasdaq · CIK 1367083
Last close1.24
Daily change-0.01 (-0.80%)
10 Years gain-99.84%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
SNOA · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 0331
Fundamental
63.4Momentum
100.0Acceleration
60.0Confidence
75.0Annual Revenue16
Quarterly Revenue50
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth19.4 / 25
Quality20.3 / 25
Capital Efficiency4.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics4.1 / 10
Forward Indicators0.7 / 5
Signals
Operating leverageOperating margin improved by 17.9582 percentage points.
Warnings
Heavy share dilution · HIGHDiluted share count increased 162.7049%.
ROIC declining · MEDIUMROIC declined by 213.7983 percentage points.
Possible growth trap · HIGHRevenue growth is high, but quality indicators are deteriorating.
Key Metrics
Revenue Growth TTM49.02%OK
Revenue CAGR 3Y13.74%OK
Gross Margin38.34%OK
Operating Margin-10.55%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-329.81%OK
Incremental Operating Margin 3Y49.52%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y162.7%OK
SBC / Revenue0.87%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 FY Mar 31, 2026 | $19.53M | $7.42M | -$2.46M | -$3.93M | -$4.13M | 37.97% | -12.6% | -21.12% | -2,221.93% | 1.68M |
| 2026 FY Mar 31, 2025 | $14.29M | $5.47M | -$3.71M | -$88,000.00 | -$168,000.00 | 38.25% | -25.97% | -1.18% | -226.41% | 1.24M |
| 2025 FY Mar 31, 2024 | $12.74M | $4.75M | -$4.70M | -$2.40M | -$2.40M | 37.26% | -36.91% | -18.85% | -93.78% | 455,000 |
| 2024 FY Mar 31, 2023 | $13.27M | $4.48M | -$4.57M | -$6.15M | -$6.42M | 33.73% | -34.43% | -48.38% | -122.61% | 3.39M |
| 2023 FY Mar 31, 2022 | $12.63M | $3.99M | -$5.89M | -$4.25M | -$4.39M | 31.62% | -46.62% | -34.72% | -213.83% | 2,653 |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $20.37M | sum latest 4 fiscal quarters Revenue | OK | 0001683168-26-006024, 0001683168-25-007938 |
| Revenue Growth TTM | 49.02% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001683168-26-006024, 0001683168-25-007938 |
| Revenue CAGR 3Y | 13.74% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001683168-26-004871 |
| Revenue CAGR 5Y | 0.95% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001683168-26-004871 |
| Gross Profit CAGR 3Y | 18.32% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001683168-26-004871 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001683168-26-006024, 0001683168-25-007938 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 38.34% | Gross Profit / Revenue | OK | 0001683168-26-006024, 0001683168-25-007938 |
| Operating Margin | -10.55% | Operating Income / Revenue | OK | 0001683168-26-006024, 0001683168-25-007938 |
| ROIC | -329.81% | NOPAT / Average Invested Capital | OK | 0001683168-26-006024, 0001683168-25-007938 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001683168-26-006024 |
| Current Ratio | 2.99x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 38.13x | (Cash + Short-term Investments) / Total Debt | OK | 0001683168-26-006024 |
| SBC / Revenue | 0.87% | SBC / Revenue | OK | 0001683168-26-006024, 0001683168-25-007938 |